Results 281 to 290 of about 75,327 (314)
Some of the next articles are maybe not open access.
Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1
Oncology Reports, 1997Tumor associated proteolysis is an essential mechanism in invasion and metastasis of cancer. The influence of the serine protease urokinase-like plasminogen activator (u-PA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) on the clinical prognosis of squamous carcinoma of the head and neck region (HNSCC) was evaluated. U-PA and PAI-1 levels
N Jan +4 more
openaire +3 more sources
Plasma Urokinase-Type Plasminogen Activator in Patients with Leukemias
Leukemia & Lymphoma, 1994Plasma levels of urokinase-type plasminogen activator (u-PA) were measured with an enzyme-linked immunosorbent assay in patients with leukemias. As compared with healthy subjects (0.73 +/- SD 0.17 ng/ml), plasma u-PA antigen level was markedly elevated in patients with acute promyelocytic leukemia (APL) (1.76 +/- 0.89 ng/ml) at disease onset. Mean u-PA
Akira Shibata +6 more
openaire +3 more sources
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2008
To investigate the level of urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR) in synovial fluid of patients with temporomandibular disorders and to analyze their relation with temporomandibular disorders (TMD).Synovial fluid was obtained from 64 sides of 56 TMD patients and from 16 sides of 10 ...
Guiquan Zhu +4 more
openaire +3 more sources
To investigate the level of urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR) in synovial fluid of patients with temporomandibular disorders and to analyze their relation with temporomandibular disorders (TMD).Synovial fluid was obtained from 64 sides of 56 TMD patients and from 16 sides of 10 ...
Guiquan Zhu +4 more
openaire +3 more sources
New developments in the urokinase-type plasminogen activator system
Expert Opinion on Therapeutic Targets, 2001The urokinase-type plasminogen activator (uPA) system plays a central role in control of cell surface proteolysis and extracellular matrix degradation. Components of this system are upregulated in a wide variety of human cancers and high levels of these proteins predict more rapid relapse and shorter survival.
openaire +2 more sources
Urokinase-Type Plasminogen Activator and PAI-1
2006Urokinase plasminogen activator (uPA) is a serine protease causally involved in tumor progression. In vivo, uPA can be inhibited by the serpin inhibitor plasminogen activator inhibitor-1 (PAI-1). However, PAI-1 is a multifunctional protein that can also play a role in cell migration, cell adhesion, angiogenesis, and apoptosis.
openaire +2 more sources
Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview
Medicinal research reviews (Print), 2014Ahmed H. Mekkawy +2 more
semanticscholar +1 more source
Plasma clearance of urokinase-type plasminogen activator
Fibrinolysis and Proteolysis, 1998Kaaden, M.E. van der +3 more
openaire +3 more sources